International Psoriasis Council

Advancing Knowledge. Improving Care.

Boehringer Ingelheim’s SPEVIGO® Receives Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA)

Boehringer Ingelheim announced that the United States Food and Drug Administration (FDA) granted Break Through Therapy Designation (BTD) to spesolimab (marketed as SPEVIGO®), an investigational treatment aimed at preventing flares in teenagers and adults suffering from generalized pustular psoriasis (GPP). Spesolimab has been granted approval by regulatory agencies for the treatment of GPP flares in nearly 40 countries.

Categories

Recent Posts

Skin-Derived Myeloid Precursors and Joint-Resident Fibroblasts Spread Psoriatic Disease from Skin to Joints

Fellow Perspectives | Psoriasis Care in Ethiopia: Challenges and Opportunities for Progress

What Matters Most to People with Psoriasis? IPC Members Help Shape a Global Answer

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

Use and Misuse of Systemic Corticosteroids in Psoriasis

In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of systemic corticosteroids in psoriasis. He questions whether they contraindicate the treatment of psoriasis, while also covering his personal experience in prescribing them.

WATCH NOW

Thursday, May 14, 2026

Use and Misuse of Topical Corticosteroids in Psoriasis

In this Take Ten with IPC video, Professor Peter van de Kerkhof discusses the use and misuse of topical corticosteroids in psoriasis, covering current use, guidelines, and consequences.

WATCH NOW

Thursday, May 14, 2026

Videos Now Available from the IEC & IPC Joint Symposium at AAD

Missed the joint symposium hosted by the International Eczema Council (IEC) and International Psoriasis Council (IPC) at the American Academy of Dermatology (AAD) Annual Meeting? Select presentations from Psoriasis or Dermatitis? When Boundaries Blur and Treatments Flip the Script are now available, covering diagnostic overlap, emerging tools, treatment-related reactions, and practical strategies for managing complex cases across diverse patient populations.

WATCH NOW

Wednesday, May 27, 2026